In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nuevolution AB

https://nuevolution.com/

Latest From Nuevolution AB

Amgen Rebuilt R&D Platform To Focus On Speed And Access

The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs. 

Business Strategies Companies

Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.

Deals Business Strategies

Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.

Commercial Companies

Almirall Taps Evotec For Novel Dermatology Mechanism

The Spanish derma specialist has agreed a research collaboration that could yield novel therapies for diseases such as psoriasis and atopic dermatitis.

Deals Dermatology
See All

Company Information

  • Other Names / Subsidiaries
    • Nuevolution A/S
UsernamePublicRestriction

Register